Cobra India (Mauritius) Limited has acquired a 2.0462% stake in Sakar Healthcare Limited through open market transactions. The acquisition involved the purchase of 489,026 equity shares, increasing the acquirer's footprint in the pharmaceutical company. The disclosure was filed in compliance with Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the transaction on June 11, 2026, Cobra India (Mauritius) Limited held 1,469,571 shares, which accounted for 6.4532% of the total share or voting capital. Following the acquisition, the entity's holding adjusted to 980,545 shares, representing 4.4069% of the total share or voting capital. The acquirer clarified that it does not belong to the promoter or promoter group of the target company.

The total equity share capital and total voting capital of Sakar Healthcare Limited remained unchanged at INR 2,22,49,910 before and after the acquisition. The total diluted share or voting capital was also reported at INR 2,22,49,910. Cobra India (Mauritius) Limited stated that there were no warrants or convertible securities acquired as part of this transaction.

Acquisition Details

The filing provided a breakdown of the shareholding changes before and after the transaction:

The mode of acquisition was specified as an open market transaction. Jean-Marc Lesieur, Director of Cobra India (Mauritius) Limited, signed the disclosure submitted to the National Stock Exchange of India Ltd. The target company's shares are listed on the National Stock Exchange of India Limited.

Sakar Healthcare Ltd reported a 74% rise in net profit to ₹3048.46 lakh for the financial year ended March 31, 2026, compared to ₹1750.20 lakh in the previous year. Revenue from operations increased to ₹25173.60 lakh from ₹17758.47 lakh in FY25, driven by the manufacturing of pharmaceutical products including liquid orals, tablets, and injections.

The Board of Directors approved the audited standalone and consolidated financial results for the fourth quarter and year ended March 31, 2026, at a meeting held on May 12, 2026. The statutory auditors, M/s. J. S. Shah & Co., issued an unmodified opinion on the financial results. The company clarified that there was no change in the financial figures or disclosures submitted earlier to the exchange, following an observation from the National Stock Exchange of India Limited.

For the quarter ended March 31, 2026, the company recorded a profit of ₹1102.43 lakh, up from ₹576.11 lakh in the corresponding quarter of the previous year. Revenue for the quarter stood at ₹7109.70 lakh. Earnings per share (EPS) for the year increased to ₹13.70 from ₹7.97 in the previous year.

Financial Performance

The company's total comprehensive income for the year rose to ₹3037.77 lakh from ₹1738.49 lakh in FY25. Total assets as of March 31, 2026, stood at ₹48109.45 lakh, compared to ₹41534.62 lakh a year ago. The company's equity reserves increased to ₹30228.78 lakh from ₹26073.12 lakh.

Corporate Governance

The Board appointed M/s. Kashyap R. Mehta & Partners, Company Secretaries, as the new secretarial auditors to fill a casual vacancy caused by the resignation of M/s. Nishant Pandya & Associates. The new auditors will hold office until the date of the ensuing Annual General Meeting. The consolidated financial results remain identical to the standalone results as the subsidiary, Sakar Oncology Private Limited, did not undertake any business transactions during the reporting period.